Mr. Benoit Battistelli (personnellement)
Directeur General, Institut National
de la Propriété Industrielle
Paris 8e

[redacted]Y.Zagyansky, Entraide, 22 rue Ste
[redacted]arthe, 75010 Paris
Paris, le 22 Juin 2004
APPLICATION N°03-08880

[redacted]

INPI PARIS 34 SP

22 JUIN 2004

Cher Monsieur le Directeur Général d'Institut National, Ca va vers gigantèsque explosion! Il peut déjà sembler que tout le Monde peut faire le crime ordonné sans aucune peur. Et je "felicite" les auteurs (logiquement de Departement français, TRES malheureusement) de "rien dire" avec ces applications d'une seulement "petite misère" dans ocean de grand crime! logiquement TOUT ORGANISé en unisson: comme TOUT EST COUVERT, TOUT EST PERMI: Directeur Général d'Organisation Mondiale de la Propriété Industrielle Kamil Idris apparaît comme criminel contre Humanité ouvert déclaré DANS OUVERTEMENT EVIDENT (sur le même ordre comme fameux Assassin Connu Joseph Désiré MOBUTU???). Je vous demontre la documentation de trop accablant par primitivité des hautes mensonges logiques vers Crime contre Humanité. On est bien sauvé pour le moment en voyant seulement dans le sable. Je vous prie de croire, Cher Monsieur, à l'expression de mes sentiments distingués. Dr.Y.Zagyansky

distingués. Dr.Y.Zagyansky

Fax: 41-22-740-14-35 VERY URGENT, and with Consequences as CRIME against Humanity! For Dossier of Appl.PCT/EP02/02302: "End of AIDS for General Virology, based on profound science as protein folding; safe vaccines, universal antimicrobial means, mad cow end"

Appl.PCT/EP02/02302
From Dr.Y.Zagyansky, Entraide, 22 rue Ste Marthe, 75010 Paris France

Mister Kamil Idris (categorically personally)
General Director of World International Patent Organization, Geneva

Paris, 17th June 2004

Dear Sir, I received WIPO letter (as answer for my Fax, PERSONALLY to you of 28/05/04 and for the same received postal letter with advice of delivery). Thank you for Civilization. But I regret very much that you ignore especially that my letter concerned the VERY EXHIBITED FORM!! the Clear and Simple "ADMINISTRATIVE TASKS (CERTAINLY FOR following LAW of PCT for "protection of inventions" performed (assures) by International Bureau" (Art.55(1)) in "searching of applications for PROTECTION!!! of inventions" (Art.1(1)): it was the PCT-LAW (PCT Request itself) that was demonstratively criminally simply, even, OPPOSED!!! with as open purpose of Brigandage. And you too clearly understood such undiscussible simplicity of law profanation with my trivial short §1,2. My protest did not concern technical details of Search: so your too naïve (for this case) statement that "IB is not competent Authority for International Search (technical- YZ) matters" must be evident expressive misleading, made to protect, in reality, the DIRECT CYNICAL CRIMINALS (usurpators of International LAW of INTERNATIONAL Search for ALL other countries!!), but not for "protection of inventions" from criminals too [Art.1(1) PCT]. Because you had to understand the above!... If Known Assassin Adolf Hitler as Chief of German Patent Office has done the same with OPEN purpose of Brigandage (and there is no difference here), you would write the same directly against law, that there is NO "protection of inventions" [Art.1(1)!!] against direct Brigandage! of Adolf Hitler. Moreover, it is with preparations of end of AIDS, cancer and mad cow (that logically is known to Robbing! Office as Crime against Humanity; and for what else to became so dirty??: it simply works!). Your silence about the OPENLY clear and concrete would dangerously confirm the above obvious charges. So in sincerely waiting the beginning of working of preparations against millions of deathes and its explosive consequences Dr.Y.Zagyansky

P.S. Please, according to law, I want to have valuable juridic copy of your too Important letter (that could be only beginning): this letter was not signed (and without number) and the date is a prior! erroneous (28.07.03.?). I did not say more now. Thank you very much in forward if you do not afraid, acting very consciously in such superenatly! (below is the copy of your letter).

From the INTERNATIONAL BUREAU

PCT

COMMUNICATION IN CASES FOR WHICH NO OTHER FORM IS APPLICABLE

To:
ZAGYANSKY, Yuly
Entraide
22 rue Sainte Marthe
F-75010 Paris
FRANCE

Date of mailing (day/month/year): 28 July 2003 (28.07.03)	
Applicant's or agent's file reference	REPLY DUE: see paragraph 1 below
International application No.: PCT/EP02/02302	International filing date (day/month/year): 04 March 2002 (04.03.02)
Applicant: ZAGYANSKY, Yuly	

1. ☐ REPLY DUE within _____ months/days from the above date of mailing
☒ NO REPLY DUE, however, see below
☐ IMPORTANT COMMUNICATION
☒ INFORMATION ONLY

2. COMMUNICATION:

The International Bureau acknowledges receipt on 29 May 2004 (29.05.04) of your facsimile letter concerning the above identified international application.

Unfortunately, as already indicated in Form PCT/IB/345 of 28 July 2003 (28.07.03), the International Bureau is not in a position to be of help in this matter as the International Bureau is not the competent Authority for international search matters.

Therefore, your letter has only been recorded but no action has been taken by the International Bureau.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Margret GODBERSEN (Fax 338 8975)
Facsimile No. (41-22) 338.89.75	Telephone No. (41-22) 338.93.28

Form PCT/IB/345 (July 1992)

Fax: 41-22-740-14-35 VERY URGENT! For Dossier of Appl. PCT/EP02/02302 "End of AIDS for General Virology, based on profound science as protein folding; safe vaccines, universal antimicrobial means, mad cow end".

Mr.Kamil Idris (personally)
General Director of World International Patent Organization, Geneva

Dr.Y.Zagyansky, Entraide, 22 rue Ste Marthe 75010 Paris
Paris, 28th May 2004

For of 3 pages: signed all 3 pages.

WITHOUT DOUBT UNLEGAL, ISA "SEARCH", MADE AS INTENTIONAL CRIMINAL SABOTAGE OF PCT CONVENTION, NOT ACCORDING TO PCT LAW, BUT FORMALLY OPENLY OPPOSITELY!!!, MUST BE CANCELED BY SUPERVISING [:Art.1(1), 51(1)] WIPO; DISCIPLINARY PENALTY CRIME OF INTENTIONAL SABOTAGE, IGNORING PCT CONVENTION] MUST BE DONE TOO.

Dear General Director! Demonstrating complete absence of law, Govemmental EPO made "Search" Oppositely to written law for this Medicinal Application of century with end of AIDS, cancer, mad cow etc. Since June 03, with help of Mrs.M.Godbersen (IB), I received (03/09/03) finally letter without any (of course!) concrete explanation of simple sabotage with Intentionally!! falsified half of signature from Director 1521 EPO Search (see below) (who must be judged for this anyway!). In spite of my clear evident answer I had no any answer neither from EPO, nor from WIPO during very long time. Only, justly in writing this letter, I received (26.05.04.) very strange letter of EPO Vice-Director, again without impossible explanation only because it is evidently impossible as anyone will surprise by simplicity!! of excess of arbitrary from below:

§1. Simply oppositely!!! to ignored PCT Convention (cited by EPO, Rule 39(i) PCT), EPO does not search claims 1, 2, 6 and 10 "as scientific theories" in knowing that this Rule obliges to make this Search according to PCT Guidelines (§9.05 In reference to this Rule!!): "When viewing claims as a whole, if theories are applied or implemented to produce a practical application or to have technical character, search is required". Consequently, partial "Search" of sole claim 3, made without claims 1 and 2 is null and THIS SEARCH DOES NOT EXIST AT ALL!

§2. Directly oppositely to ignored law, EPO does not search claims 4, 5, 7-9, 11, 12 as generally for "large number of possible compounds" for use in therapy method. But directly according to law [cited in all these claims Art.52(4)], in EPC (itself!) (Art.52), there are specially given references, obliging EPO to make search of the process of therapeutic method for being new and inventive with always given by me examples of substances for manufacture of such medicaments. It is too primitive sabotage in Medicine (AIDS, cancer, mad cow!) based on processes "upon living things" ("PCT Guidelines" §5.12). Moreover, Search of above claims must be dons with basic scientific theories (§1) as a whole [Rule 39(i) PCT].

§3. And the above (§1, 2) was "the reason" of demonstrative sabotage of all Search! and, of course (see also §5), of cynic absence of impossible explanations. But "problem" became urgent: I must enter in many National stages without Search (instead of best Search for XXII century preparations) due to only demonstrative sabotage to Search oppositely to PCT against initial PCT Request!

§4. UP TO EPO: EPO is obliged to do this Urgent Search (a) with original text (even with better!! claims!!) or (b) with text certainly unsignificantly modified (for EPO, too) or (c) with original and after this with little modified text: UP TO EPO: it is not TOO PRIMITIVE obstacle and EPO asked nothing else during "Search" (§1).

§5. EPO responsible persons (Chief of Unity and Vice-President!) wrote that "there is no provision for review or appeal" at International phase. It is too simple open misinformation. "EPO must, in carrying out International Search, be guided by the PCT Search Guidelines" (EPO Guidelines §Bill-4.4, "Case Law of Boards of Appeal of EPO" §IX.C.1.). And these Guidelines obliges EPO (§1.04): "Re-view of action of the Authority (ISA)" should take place when "such review is provied for under the applicable national law and practice". Wherein National EPO law stipulates: "Any decision of departments of the EPO are subject to review before a Board of Appeal" ("EPO Guidelines" General Introduction §3.2). Independently DE FACTO, it is ALSO directly confirmed by EPO Law ("Case Law", p.574): "There is no obstacle to making use of appeal procedures provided for under the EPC to supplement the provisions of the PCT" (with EPO as Designed Office too). Moreover, "all (according to EPO: EPO is 100% includedl) PCT authorities in fact accept and duly consider any request for reconsideration"! ""Cass Law", p.574!

But MOREOVER, the given EPO misinformation a priori CANNOT take place! With the same obvious §1,

(both pages are signed)

2, at this same good text and THE SAME very good claims, EPO National phase must have good complete Search (as with any other good Application even with OBJECTIVE EPO errors) without additional payment. So by criminal Intentional sabotage, I MUST lose International Search for all countries (without any my fault????), that will be good only at EPO National stage. It is impossible and incredible a priori!, that is confirmed by above LAW!

But moreover, at Intentional penal Totalitarian, Ignoring PCT Convention (it means of Requsstil and WIPO must immediately stop the ignoring of PCT Law) (§1,2!), the Disciplinary Board of Appeal ("Law case" VIII-3.1.) punishes such penal crime too: "As such these provisions ("European Convention of Protection of Human Rights") should be considered part of the legal system of this Organization (EPO) and should be observed by all its departments" (wherein "penality" must be "proportionate to the seriosness of the charges"- milliards of euros and Crime against Humanity, justly).

SO THE "PROBLEM" IS ONLY IN §1 and 2, that are too obvious formally. And justly the EPO SPECIALISTS EXPRESSIVELY do not discuss it at all because, OF COURSE, it is impossibly evident!

Thank you very much for stopping of intentional criminal Brigandage, wherein WIPO is also responsible for above demonstrative crime according to Art.1(1) and 51(1) PCT and Request. Sincerely yours Dr.Y.Zagyansky (e-mail Kamil.idris@wipo.int- became unworking).

Supplements: Monstrous direct documents proving that European Governments are Brigands and law Usurpers à la Palermo (as only EXAMPLES).

a). Demonstrative criminal usurping falsification of EPO Unity Director. As one can see the level of Director of EPO Search Unity E. De Bandel intentionally falsified the signature (making its half- ass below), moreover without sending of any juridically valid document since half of year). It is already irreversibly intentionally penal comme made by European Governments.

b). Falsification in forward à LA PALERMO. EPO tries by anyway to stop my Application PCT/IB00/00843- EP938554.5 (with exemplary complete Search without any X and Y but with similar General scientific base construction). Wherein EPO's obstacle was in reality only crashable opposite sense of Rule 39(i) PCT. So, logically, they tried to falcify the unlegal returning again to Examination. "So" in many years later!! de facto they wrote (Directorate General 2!) that there is no Priority document neither in WIPO nor in EPO. It was a priori à la Palermo: there were 4 copies in 4!!! Departments! (proven!!). It is difficult days for falcificators of evident patent! See separate page of signed by me papers

It is evident, that the responsible intentional falsificators of European Governments must be exemplary punished by at least "Disciplinary Board of Appeal", that could be later "Tribunal of Nuremberg" as Crime against Humanity with this very important Medicinal Applications. Earth must be burnt under foots of intentional very responsible falcificators!

(both pages are signed). Separate letter to Mrs. Godbersen is in the same envelope.

The procedure before the International Searching Authority (ISA) was closed by virtue of establishing and sending the International Search Report. There is no provision for review or appeal. Thus, the EPO can not grant your request to withdraw or amend the International Search Report.

As a final point, it should be mentioned that once you proceed into the regional phase before the EPO, a search may be carried out should the problems which led to the non-establishment of the Search Report in respect of certain claims be overcome (see "Guidelines for Examination in the EPO", B-VIII, 6.). Your arguments and proposed amendments of description and claims may then be taken into account.

Yours sincerely,

pp

E. De Bundel,
Director 1521

Fax: 41-22-740-14-35 VERY URGENT! For Dossier of Appl. PCT/EP02/02302 "End of AIDS for General Virology, based on profound science as protein folding: safe vaccines, universal antimicrobial means, mad cow end".

Mr.Kamil Idris (personally) Dr.Y.Zagyansky, Entraide, 22 rue Ste Marthe 75010 Paris
General Director of World International Paris, 28th May 2004
Patent Organization, Geneva

Fax of 3 pages: Signed all by me Y.Z.

WITHOUT DOUBT UNLEGAL, ISA "SEARCH", MADE AS INTENTIONAL CRIMINAL SABOTAGE OF PCT CONVENTION, NOT ACCORDING TO PCT-LAW, BUT FORMALLY OPENLY OPPOSITELY!!!, MUST BE CANCELED BY SUPERVISING [:Art.1(1), 51(1)] WIPO: DISCIPLINARY PENALTY CRIME OF INTENTIONAL SABOTAGE, IGNORING PCT CONVENTION! MUST BE DONE TOO.

Dear General Director! Demonstrating complete absence of law, Governmental EPO made "Search" Oppositely to written law for this Medicinal Application of century with end of AIDS, cancer, mad cow etc. Since June 03, with help of Mrs.M.Godbersen (IB), I received (03/09/03) finally letter without any (of course!) concerete explanation of simple sabotage with intentionally!! falsified half of signature from Director 1521 EPO Search (see below) (who must be judged for this anyway!). In spite of my clear evident answer I had no any answer neither from EPO, nor from WIPO duiring very long time. Only, justly in writing this letter, I received (26.05.04.) very strange letter of EPO Vice-Director, again without impossible explanation only because it is evidently impossible as anyone will surprise by simplicity!! of excess of arbitrary from below:

§1. Simply oppositely!!! to ignored PCT Convention [cited by EPO, Rule 39(i) PCT], EPO does not search claims 1, 2, 6 and 10 "as scientific theories" in knowing that this Rule obliges to make this Search according to PCT Guidelines (§9.05 in reference to this Rule!!): "When viewing claims as a whole, if theories are applied or implemented to produce a practical application or to have technical character, search is required". Consequently, partial "Search" of sole claim 3, made without claims 1 and 2 is null and THIS SEARCH DOES NOT EXIST AT ALL!

§2. Directly oppositely to ignored law, EPO does not search claims 4, 5, 7-9, 11, 12 as generally for "large number of possible compounds" for use in therapy method. But directly according to law [cited in all these claims Art.52(4)], in EPC (itself!) (Art.52), there are specially given references, obliging EPO to make search of the process of therapeutic method for being new and inventive with always given by me examples of substances for manufacture of such medicaments. It is too primitive sabotage in Medicine (AIDS, cancer, mad cow!) based on processes "upon living things" ("PCT Guidelines" §5.12). Moreover, Search of above claims must be done with basic scientific theories (§1) as a whole [Rule 39(i) PCT].

§3. And the above (§1, 2) was "the reason" of demonstrative sabotage of all Search! and, of course (see also §5), of cynic absence of impossible explanations. But "problem" became urgent: I must enter in many National stages without Search (instead of best Search for XXII century preparations) due to only demonstrative sabotage to Search oppositely to PCT against initial PCT Request!

§4. UP TO EPO: EPO is obliged to do this Urgent Search (a) with original text (even with better!! claims!!) or (b) with text certainly unsignificantly modified (for EPO, too) or (c) with original and after this with little modified text: UP TO EPO: it is not TOO PRIMITIVE obstacle and EPO asked nothing else during "Search" (§1).

§5. EPO responsible persons (Chief of Unity and Vice-President!) wrote that "there is no provision for review or appeal" at International phase. It is too simple open misinformation. "EPO must, in carrying out international Search, be guided by the PCT Search Guidelines" (EPO Guidelines §BIII-4.4, "Case Law of Boards of Appeal of EPO" §IX.C.1.). And these Guidelines obliges EPO (§1.04): "Re-view of action of the Authority (ISA)" should take place when "such review is provied for under the applicable national law and practice". Wherein National EPO law stipulates: "Any decision of departments of the EPO are subject to review before a Board of Appeal" ("EPO Guidelines" General Introduction §3.2). Independently DE FACTO, it is ALSO directly confirmed by EPO Law ("Case Law", p.574): "There is no obstacle to making use of appeal procedures provided for under the EPC to supplement the provisions of the PCT" (with EPO as Designed Office too). Moreover, "all (according to EPO: EPO is 100% included!) PCT authorities in fact accept and duly consider any request for reconsideration"! ""Case Law", p.574!

But MOREOVER, the given EPO misinformation a priori CANNOT take place! With the same obvious §1,

(both pages are signed) Y.Z.

2, at the same good text and THE SAME very good claims, EPO National phase must have good complete Search (as with any other good Application even with OBJECTIVE EPO errors) without additional payment. So by criminal intentional sabotage, I MUST lose International Search for all countries (without any my fault???), that will be good only at EPO National stage. It is impossible and incredible a prioril, that is confirmed by above LAW!

But moreover, at intentional penal Totalitarian, ignoring PCT Convention (it means of Request!! and WIPO must immediately stop the ignoring of PCT Law) (§1,2!), the Disciplinary Board of Appeal ("Law case" VIII-3.1.) punishes such penal crime too: "As such these provisions("European Convention of Protection of Human Rights") should be considered part of the legal system of this Organization (EPO) and should be observed by all its departments" (wherein "penality" must be "proportionate to the seriosness of the charges"- milliards of euros and Crime against Humanity, justly).

SO THE "PROBLEM" IS ONLY IN §1 and 2, that are too obvious formally. And justly the EPO SPECIALISTS EXPRESSIVELY do not discuss it at all because, OF COURSE, it is impossibly evident!

Thank you very much for stopping of intentional criminal Brigandage, wherein WIPO is also responsible for above demonstrative crime according to Art.1(1) and 51(1) PCT and Request. Sincerely yours Dr.Y.Zagyansky (e-mail Kamil.Idris@wipo.int- became unworking).

Supplements: Monstrous direct documents proving that European Governments are Brigands and law Usurpers à la Palermo (as only EXAMPLES).

a). Demonstrative criminal usurping falsifiction of EPO Unity Director. As one can see the level of Director of EPO Search Unity E. De Bandel intentionally falsified the signature (making its half!- see below), moreover without sending of any juridically valid document since half of year). It is already irreversibly intentionally penal comme made by European Governments.

b). Falcification in forward à LA PALERMO. EPO tries by anyway to stop my Application PCT/IB00/00843- EP938954.5 (with exemplary complete Search without any X and Y but with similar General scientific base construction). Wherein EPO's obstacle was in reality only crashable opposite sense of Rule 39(i) PCT. So, logically, they tried to falcify the unlegal returning again to Examination. "So" in many years later!! de facto they wrote (Directorate General 2!) that there is no Priority document neither in WIPO nor in EPO. It was a priori à la Palermo: there were 4 copies in 4!!! Departments! (proven!!). It is difficult days for falcificators of evident patent! See separate page of signed by me proofs Y.Z.

It is evident, that the responsible intentional falsificators of European Governments must be exemplary punished by at least "Disciplinary Board of Appeal", that could be later "Tribunal of Nuremberg" as Crime against Humanity with this very important Medicinal Applications. Earth must be burnt under foots of intentional very responsible falcificators!

(both pages are signed). Separate letter to Mrs. Godbersen is in the same envelope

The procedure before the International Searching Authority (ISA) was closed by virtue of establishing and sending the International Search Report. There is no provision for review or appeal. Thus, the EPO can not grant your request to withdraw or amend the International Search Report.

As a final point, it should be mentioned that once you proceed into the regional phase before the EPO, a search may be carried out should the problems which led to the non-establishment of the Search Report in respect of certain claims be overcome (see "Guidelines for Examination in the EPO", B-VIII, 6.). Your arguments and proposed amendments of description and claims may then be taken into account.

Yours sincerely,

P.p.

E. De Bandel,
Director 1521

Y.Z. 18th August 2004 for USPTO

18 August 2004 End Fax Y.Z. Copy of Int. Appl. PCT/EP02/02302 "End of AIDS" 4 pages

Yuji Iwasaki 18th Aug. 2004 3rd Exp.

end p. 8 [redacted] exp: „ also „ Guidelines "
§C III – 2.2.1 and "
beginning Declaration about only doc !
" Declaration about only doc Simple
observations from dependent claims of
references doc several previous claims ".

638,98,1991. 62.Ann.N.Y.Acad.Sci. 638,361,1991. 63.Oncogene 5,755,1999. 64.Protein Profile 2, 1173,1995. 65.Eur.J.Biochem. 232,425,1995. 66.Endocrine J. 2,249,1994. 67.EMBO J. 5,891,1986. 68.Proc.Natl.Acad.Sci.USA 82,7889,1995. 69.Breast Canc.Res.Treat. 40,231,1996. 70.Cancer Biochem.Biophys. 15,67,1995. 71.Curr.Opin.Cell.Biol. 5,48,1993. 72.Mol.Cel.Biol. 8,1775,1998. 73.J. Neurosci. 14,1130,1994. 74.J.Cell Biol. 126,1221,1994. 75.Differentiation 14,123,1979. 76.Biochem. J. 316,713,1996. 77.Biophys.J. 74,1914,1996. 78.Am.J.Physiol.-Cell Physiol. 39,C1532,1996. 79.Biol. Cell 84,139,1995. 80.Mol.Cell.Biol. 12,685,1992. 81.Nucl.Acid.Res. 23,2388,1995. 82.Mol.Cell.Biol. 13, 1572,1993. 83.Gen.Devel. 5,1464,1991. 84.Cell 61,255,1990. 85.Mol.Cell.Biol. 16,5444,1996. 86.Curr. Biol. 5,477,1993. 87.J.Med.Biol.Res. 29,895,1996. 88.Nucl.Acid.Res. 24,1753,1996. 89.EMBO J. 7, 3559,1988. 90.Nucl.Acid.Res. 23,4712,1995. 91.Mol.Cell.Biol. 9,5073,1989. 92.J.Cell.Biol. 115,887, 1991. 93.J.Biol.Chem. 266,19867,1991. 94.Mol.Cell.Biol.8,2737,1988; Publ. FR-98-06910. 95.Eur.J. Biochem. 63,166,1994. 96.Biochem.Soc.Transac. 24,521,1996. 97.Mol.Cell.Biol. 14,7984,1994. 98.J. Cell Biol. 126,1221,1994. 99.J.Neurosci. 16,1346,1996. 100.Gen.Compar.Endocrinol. 103,316,1996. 101.Nucl.Acid.Res. 24,4078,1996. 102.Eur.J.Neurosci. 7,2249, 1995. 103.Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2.Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3.Adv.Exp.Med.Biol. 384,123,1995, 4.J.Neurophysiol. 78,3061,1997. 5.J.Neurophysiol. 78,3061,1997. 6."Epilepsy. A Comprehensive test book", Ed.Engel J. & Pedby TA, 3 vol. (Lippincott-Raven,Phil,1998). 7.Berne RM & Levy MN "Physiology" (CV Mosby Company, St.Louis, 1988). 8.Biophys. J. 68 (4 Suppl.),55S,1995.

Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or acivities reffered to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organizatiuon "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary scholl since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and

Yuf Regs 18th Aug. 04 2nd exp.
end p. 87 (e[redacted]1): " §C111-2.2.] and "
beginning exp. 3 p. 97: " 638, 98, 1991. 62. Ann. N. Y."

638,98,1991. 62.Ann.N.Y.Acad.Sci. 638,361,1991. 63.Oncogene 5,755,1999. 64.Protein Profile 2, 1173,1995. 65.Eur.J.Biochem. 232,425,1995. 66.Endocrine J. 2,249,1994. 67.EMBO J. 5,891,1986. 68.Proc.Natl.Acad.Sci.USA 82,7889,1995. 69.Breast Canc.Res.Treat. 40,231,1996. 70.Cancer Biochem.Biophys. 15,67,1995. 71.Curr.Opin.Cell.Biol. 5,48,1993. 72.Mol.Cel.Biol. 8,1775,1998. 73.J. Neurosci. 14,1130,1994. 74.J.Cell Biol. 126,1221,1994. 75.Differentiation 14,123,1979. 76.Biochem. J. 316,713,1996. 77.Biophys.J. 74,1914,1996. 78.Am.J.Physiol.-Cell Physiol. 39,C1532,1996. 79.Biol. Cell 84,139,1995. 80.Mol.Cell.Biol. 12,685,1992. 81.Nucl.Acid.Res. 23,2388,1995. 82.Mol.Cell.Biol. 13, 1572,1993. 83.Gen.Devel. 5,1464,1991. 84.Cell 61,255,1990. 85.Mol.Cell.Biol. 16,5444,1996. 86.Curr. Biol. 5,477,1993. 87.J.Med.Biol.Res. 29,895,1996. 88.Nucl.Acid.Res. 24,1753,1996. 89.EMBO J. 7, 3559,1988. 90.Nucl.Acid.Res. 23,4712,1995. 91.Mol.Cell.Biol. 9,5073,1989. 92.J.Cell.Biol. 115,887, 1991. 93.J.Biol.Chem. 266,19867,1991. 94.Mol.Cell.Biol.8,2737,1988; Publ. FR-98-06910. 95.Eur.J. Biochem. 63,166,1994. 96.Biochem.Soc.Transac. 24,521,1996. 97.Mol.Cell.Biol. 14,7984,1994. 98.J. Cell Biol. 126,1221,1994. 99.J.Neurosci. 16,1346,1996. 100.Gen.Compar.Endocrinol. 103,316,1996. 101.Nucl.Acid.Res. 24,4078,1996. 102.Eur.J.Neurosci. 7,2249, 1995. 103.Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2.Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3.Adv.Exp.Med.Biol. 384,123,1995, 4.J.Neurophysiol. 78,3061,1997. 5.J.Neurophysiol. 78,3061,1997. 6."Epilepsy. A Comprehensive test book", Ed.Engel J. & Pedby TA, 3 vol. (Lippincott-Raven,Phil,1998). 7.Berne RM & Levy MN "Physiology" (CV Mosby Company, St.Louis, 1988). 8.Biophys. J. 68 (4 Suppl.),55S,1995.

Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or acivities reffered to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organizatiuon "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary scholl since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and

Yu [redacted] 18 th Aug. 2004 18 Exp.
end p. 82 [redacted] exp.): „ Int. J. Pharmaceut. 134, 173, 1996. [redacted] Exs "
(18 Exp beginning p. 87 :„ 638, 98, 1991, 62. Aarh. "

638,98,1991. 62.Ann.N.Y.Acad.Sci. 638,361,1991. 63.Oncogene 5,755,1999. 64.Protein Profile 2, 1173,1995. 65.Eur.J.Biochem. 232,425,1995. 66.Endocrine J. 2,249,1994. 67.EMBO J. 5,891,1986. 68.Proc.Natl.Acad.Sci.USA 82,7889,1995. 69.Breast Canc.Res.Treat. 40,231,1996. 70.Cancer Biochem.Biophys. 15,67,1995. 71.Curr.Opin.Cell.Biol. 5,48,1993. 72.Mol.Cel.Biol. 8,1775,1998. 73.J. Neurosci. 14,1130,1994. 74.J.Cell Biol. 126,1221,1994. 75.Differentiation 14,123,1979. 76.Biochem. J. 316,713,1996. 77.Biophys.J. 74,1914,1996. 78.Am.J.Physiol.-Cell Physiol. 39,C1532,1996. 79.Biol. Cell 84,139,1995. 80.Mol.Cell.Biol. 12,685,1992. 81.Nucl.Acid.Res. 23,2388,1995. 82.Mol.Cell.Biol. 13, 1572,1993. 83.Gen.Devel. 5,1464,1991. 84.Cell 61,255,1990. 85.Mol.Cell.Biol. 16,5444,1996. 86.Curr. Biol. 5,477,1993. 87.J.Med.Biol.Res. 29,895,1996. 88.Nucl.Acid.Res. 24,1753,1996. 89.EMBO J. 7, 3559,1988. 90.Nucl.Acid.Res. 23,4712,1995. 91.Mol.Cell.Biol. 9,5073,1989. 92.J.Cell.Biol. 115,887, 1991. 93.J.Biol.Chem. 266,19867,1991. 94.Mol.Cell.Biol.8,2737,1988; Publ. FR-98-06910. 95.Eur.J. Biochem. 63,166,1994. 96.Biochem.Soc.Transac. 24,521,1996. 97.Mol.Cell.Biol. 14,7984,1994. 98.J. Cell Biol. 126,1221,1994. 99.J.Neurosci. 16,1346,1996. 100.Gen.Compar.Endocrinol. 103,316,1996. 101.Nucl.Acid.Res. 24,4078,1996. 102.Eur.J.Neurosci. 7,2249, 1995. 103.Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2.Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3.Adv.Exp.Med.Biol. 384,123,1995, 4.J.Neurophysiol. 78,3061,1997. 5.J.Neurophysiol. 78,3061,1997. 6."Epilepsy. A Comprehensive test book", Ed.Engel J. & Pedby TA, 3 vol. (Lippincott-Raven,Phil,1998). 7.Berne RM & Levy MN "Physiology" (CV Mosby Company, St.Louis, 1988). 8.Biophys. J. 68 (4 Suppl.),55S,1995.

Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or acivities reffered to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organizatiuon "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary scholl since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and

18 th Aug. 2004 3a exp.
end exp. p. 82 :, 134, 193, 1936. 13. Ex 5"
beginning p. 87 (1st exp) :, 6-38, 98, 1991."

3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996. 36.J.Acquir.Immune Defic.Syndr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene 13,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996. 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65. J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995. 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual motion, development: seisms, extinguished volcans, created islands, Big Bang Energy" - full text in http://pctgazette.wipo.int 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.

Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,(Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).

Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bioessays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS

18th August 2004 2nd exp.

end of 1st [redacted] p. 82:" 13. EXS

beginning 3d exp. p. 82:" 3,965, 1990. 26. Immunol.

Today 13,301, 1992. 27. Microbiol. Rev. 57, ..."

3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996. 36.J.Acquir.Immune Defic.Syndr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene 13,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996. 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65. J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995. 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual motion, development: seisms, extinguished volcans, created islands, Big Bang Energy" - full text in http://pctgazette.wipo.int 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.

Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,(Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).

Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bioessays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS

Y.S. Bagpi 18 Aug. 04 1ST exp.

end of „Delh[redacted] abst optional conditions":
„2720506, [redacted]622 + New Amended Sheet"
beginning of 2nd exp p. 82: „3,965,1990. 26 Immunol.
May 13, ..."

3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996. 36.J.Acquir.Immune Defic.Syndr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene 13,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996. 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65. J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995. 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual motion, development: seisms, extinguished volcans, created islands, Big Bang Energy" - full text in http://pctgazette.wipo.int 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.

Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,(Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).

Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bioessays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS

DECLARATION ABOUT OPTIONAL CORRECTION OF SLIPS IN pages 82 and 87.

I, Zagyansky Yuly, sole inventor of Application PCT/EP02/02302, make the followoing optional corrections of slips. Slips. p.82 (lines 35-37): missed (but cited) references in Part. VI (N°N°5-10). p.87 (lines 15-21): missed (but cited) References of Chapters XI and Annex IIIA. p.87 (22-39): exactly retyped "Important supplement for Search" without mention of AT Office (it was impossible alternative for ISA). [Below, see page 52 with accepted by IPEA numerous new references in Specification for my Application PCT/IB00/00843]. Paris, 11th August 2004. All pages are signed by me verso with date of 08/11/04.

Yuly Zagyansky 18th August 2004

IB0000843

one of Art.52(3) these subject-matters (like discoveries and scientific theories) are patentable only with their applications (!). Consequently, the claims, concerning "Theory or (EVEN!) principle underlying the invention" (letter "T" according the Form of the EPO Research) (to see also "Guidelines.." §CIII-2.2.) and claims, concerning their practical consequences must be considered ONLY ENSEMBLE, according to the law. Consequently, I present here the (priliminary) International Classification of Patents with the mentions of the corresponding claim Groups, serving to the establishment of each I.C.P. element.

Claims 1,2,3,5: H02K 44/00; G01P 3/50; G01B 11/03; G01R 5/00, 33/00; G01T 5/00; G01J 3/00. Claims 3,4,6: G01T 1/00; G01J 3/00; G21H 7/00; G21K 1/00, 7/00; G02B 23/00; G01B 15/00; G21G 1/00, 5/00. Claims 3,4,7: G01T 1/00, 7/00, 7/02, 7/04, 7/06, 3/00; G21G 1/00, 5/00; H05H 6/00; G21C 23/00; G21K 5/08; G21D 5/00; G01T 7/02. Claims 3,4,8: G21K 1/00; H02N 1/00; H02K 44/00; G01V 7/00. Claims 3,4,9: G01P 3/50; G01B 11/03; G02B 23/00; H01H 35/02; B65G; B65G 47/22. Claims 3,4,10: G01R 5/00, 33/00; G01J 3/00; G01T; G01W 1/00; G01V 3/00. Claims 3, 4,11: G01R 5/00, 33/00; G01J 3/00; G01T; G01W; G01V 1/00, 3/00, 1/104, 1/157; E02B 17/00; E02F. Claims 3,4,12: G21K 1/00, 5/08, 7/00; H02N 1/00.

Unity of Invention (S-03 /1998, "Gazette du PCT"). I develop here the New Atomic Scale (Microworld) Physics (instead of the "Einstein-Bohr" Physics of XX century, established by Greatest geniuses) with this "sole general" conception with absolutely (and often opposite) new principal bases and revolutionary (for milliards of years) concrete applications. Evidently such new field (even the new Science!) general invention entitles the new general claims /".. an invention which open up a whole field is entitled to more generally in the claims than one which is concerned with advances in a known technology" ("Guidelines.."- §CIII-2.2.)/. But I guarantee the Unity of Invention also (also) with the help of the discovered New Force in the Atom, conducting futher to the net negation of all basic foundations of the Einstein-Bohr Physics, constructed from beginning of XX century and to the creation of the Absolutely New Atomic scale Physics. with the titanic applications in the sure continuous chain of the sure inventive discoveries, "considered as one whole, relatively to the technical field" where the developed continuous components of these chains (claims) "contain all characteristics of the previous ones" ("Gazette du PCT" S-03/1998 p.46). So the Unity of Invention is made in the double form.

MANY BEST PATENTS OF COMMON MEANS, FITTING TO GIVEN CODES, EASILY TAKEN FROM CD-ROM.

(p.48): a. H01H 35/02, B95G 47/00, B65G 47/22: WO 00/21052, 89/10623, 84/04962, 00/01921, 01/27006; EP:707193, 595446, 813214, 480131, 463291, 253790, 124269, 706028, 305940, 125839, 502248, 124269; FR 2560115, 2519947; 2490197. b, c. G01V (3/00, 1/00), G01W 1/00: WO 01/77712, 00/13647, 01/38903, 00/77755, 00/51093, 95/25966, 01/77702, 01/79873, 99/13358, 98/53345, 98/19750 91/19210; EP 1120629, 718639, 829736, 422895; FR 2779530, 2542453, 2424542, 2670532. G01V 1/104, 1/157, E02F, E02B 17/00: WO 00/63724, 97/48967, 92/11546, 90/13830, 01/79614, EP 1136648, 518427, 1147265. d. G21K 1/00, H02N 1/00, H02K 44/00: WO 00/14750, 00/14759, EP 1112578, 235896. (p.18): G01T 7/02, /04, /06: WO 00/69769, 00/25152; EP 234150, 404681, 008967; FR 2770648, 2729765, 2720506, 2619622.

New

AMENDED SHEET

Yuli Prague 18th August 04

end of a[illegible]ed to Form PTO-1390 cheque:
"2. Form PCT/IB/308. Yuli Prague 11 August 2004
with attached to this Form cheque N°20720
for $460 (by four staples). (1 January 2004)
legislative of Leys. page 82: "3,965, 1990. 26. Im-
munology. Today.."

CODE:
AGENCE: SOCIÉTÉ GÉNÉRALE
GROUPE PARIS SEINE AMONT
LOGISTIQUE UNIFIÉE
31/35 Rue Froideveaux
(FRANCE) 75014 PARIS
S.G. 03085

SOCIETE GENERALE
A FRENCH BANK FOUNDED IN 1864

08072

PARIS LE 10/08/ 2004

1-2
210

DOLLARS-U.S.$ 460,-

SOCIETE GENERALE 460.00 USD

TO THE ORDER OF COMMISSIONER OF PATENTS AND TRADE MARKS

PAYABLE AT OF USPTO

JPMORGAN CHASE BANK
NEW YORK, NY 10017

P. 1216 Ed. 04.2003

"080720" :021000021:00171435 9"

SOCIETE GENERALE
AGENCE S.G. 03085
(FRANCE)

DETACH AND RETAIN THIS VOUCHER
THE ATTACHED CHECK IS IN PAYMENT OF ITEMS DESCRIBED BELOW.
IF NOT CORRECT PLEASE NOTIFY US PROMPTLY. NO RECEIPT DESIRED.

DATE	DESCRIPTION	AMOUNT
10/08/2004	VIRT. D'ORDRE Mme ZAGYANSKY.	USD 460,

DELUXE BUSINESS FORMS 1+800-328-0304

VBG097.CDR

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13*ter*.2 and 37 CFR 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: 1.Covering letter with cheque for $460 and letter Supplement; 2.Form PCT/IB/308.

Yulia Zagyansky 18th August 2004

Yulia Zagyansky 11 August 2004

with attached to this Form cheque N° 080720 for $460 (by four staples)

(1 January 2004)

Yuksel 18th August 2004

[redacted]PTO/SB/09:„ Commissioner for Patents, Washington, DC 20231 "

heading of declaration about optional correction of slips: " I, Zagyansky Yuly, sole inventor of Application PCT/EP02/02302, make ..."

Yuf Tagu 18th August 2004
end of envelope Chronopost:
" ou 0825 801 801 *0,98F TTC (0,14€) la minute au 01/01/2000 " Yuf Tagu
beginning of page form PTO-1390: Form PTO-1390 (Rev. 10-2000) U.S. DEPARTMENT OF..."

IMPORTANT! AT SENDING OF MONEY AT POST, AT CHECKING, I HAD PUT THE CITY „ALEXANDRIA" IN ALL THREE COPIES OF „MANDAT INTERNATIONAL" WITH MY SPECIAL BLACK SIGNATURE PEN, AS HERE

Yuf Tagu 18 August 2004
18th August 2004

VERSO

LETTRE N°1

LA POSTE **FICHE DE DÉPÔT D'UN ENVOI INTERNATIONAL** - RECOMMANDÉ - ~~AVEC VALEUR DÉCLARÉE~~

A remplir par l'expéditeur

Destinataire : Mail Stop PCT, Commissioner for Patents, US Patent and Trademark Office, P.O. Box 1450, Alexandria 22313-1450

Localité Alexandria, Pays Virginia, USA

Réservé au service

75100 PARIS LOUVRE RP

date N°	AR	PR Prix	*H	vd	Nature	signature de l'agent
étiquette 510 16/08/04		12.50EUR 81.99FRF	ES			
08665		0206g	Poids		crbt	

517/517 bis

VOIR AU DOS

RCS Nanterre B 356 000 000

LA POSTE

MANDAT INTERNATIONAL

PAYS DE DESTINATION USA

☐ EXPRESS ☐ AUTRE - non urgent

Ecrivez en majuscules, lisez bien les précisions figurant au verso ⇨

MONTANT

Montant à transférer 460,000 (Montant en chiffres) Devise USD (dollar USA)

quatre cent soixante dollars US (Montant en lettres)

EXPEDITEUR ☐ Madame ☐ Mademoiselle ☒ Monsieur

ZAGYANSKY

Nom de l'expéditeur (ou raison sociale de l'entreprise)

YULY

Prénoms

Adresse (pour remboursement du mandat en France en cas de non paiement)

6 CENTRALE, 22 RUE STE MARTHE

75010 PARIS

Code postal *Ville*

Numéro de téléphone (pour vous joindre en cas de problème)

BENEFICIAIRE ☐ Madame ☐ Mademoiselle ☐ Monsieur

COMMISSIONER FOR PATENTS

Nom du bénéficiaire (ou raison sociale de l'entreprise)

Prénoms

☒ PAIEMENT EN ESPECES

Adresse du bénéficiaire

UNITED STATES PATENT AND TRADMARK

OFFICE, P.O. BOX 1450, ALEXANDRIA

22313 VIRGINIA, USA

Ville

1450 *Code postal* *Région ou état*

☐ VERSEMENT SUR UN COMPTE POSTAL (non admis en express) : Centre de chèques :

Compte du bénéficiaire

MESSAGE A TRANSMETTRE AU BENEFICIAIRE (admis selon les pays, se renseigner au guichet)

APPL. PCT/EP02/02302, BASIC FEE,

APPLICANT ZAGYANSKY

OPTION EXPRESS : Notification au bénéficiaire par ☒ Fax ☐ Téléphone ☐ E-mail (voir au verso)

FAX: 17038729306

MANDAT INTER - 4 803 853 - 611471

PAYS : AMERIQUE(ETATS-UNIS)

Bureau	Date	Numéro	Catégorie	Montant transféré	Montant déposé		Service
756250	16/08/04	0023	ESPE	******460.00 USD	386,55 EUR	2535.60 FRF	
					Frais 17,30 EUR	113.48 FRF	
					Taxe 0,00 EUR	0.00 FRF	
1 EUR = 6.559570 FRF				TOTAL PERCU	403,85 EUR	2649.09 FRF	

1 EUR = 1.190000 USD BUREAU : PARIS ODEON

Cadre réservé aux opérations manuelles

Bureau	Date	Numéro	Catégorie	Montant transféré	Montant déposé en euros

Frais

TOTAL PERÇU

MDT 015 / Version 05/2002

PARIS-ODEON-(69) 6, RUE DE L'ECOLE DE MEDECINE 75006 PARIS-BD ST GERMAIN

RCS PARIS 356 000 000

RECEPISSE A REMETTRE AU CLIENT

18th August 04

VERSO

Selon la loi Informatique et Libertés, N°78/17 du 6 janvier 1978, vous bénéficiez d'un droit d'accès et de rectification pour toutes les informations vous concernant.

CHRONOPOST SA — Dr.Y.Zagyansky, Entralde, 22 rue Ste Marthe, 75010 Paris
14 Bd des Freres Volsin 92795 — Envoi N°XD104666931FR
Issy les Moulineaux Cedex 9 — Paris, le 16 Aôut 2004

Monsieur, §1. J'ai envoyé "Chronopost" le 11 Aôut 04 selon Instruction publiée par Office Gouvernemental des Brevets des USA dans Livre Officiel (voir aussi www.uspto.GOV) comme milliers et milliers des autres Applicants pour brevets (beaucoup plus de 100 000 Applicants/an). Mais de plus j'ai collé (par scotch transparent, comme étiquette sur beaucoup des lettres) l'adresse geographique (avec addresse postale) copiée de ce livre officiel de legislation! (voir copie d'enveloppe) (avec aussi le couleur bleu trop visible). (adresse postale officielle: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, USA, adresse georgaphique 220 20th Street S., Crystal Plaza 2, Arlington, Virginia, 22202, USA- voir copie d'enveloppe! les deux!!!).

§2. Internet m'a communiqué que "livraison effectuée" était le 12/08 à 17h31. Heureusement, j'ai compris que c'est absurd (qui devait justement être LE PLUS fatal pour moi avec perte des milliards de brevet potentialisél comme c'est exprès). "Livraison" a eu lieu seulement 2 heures après arrivée au aeroport de New York. Mais Office se trouve à 350 km de cela (voir la carte) à la partie sud de Washington D.C. Pour 100% cette "livraison" (même avec DES ADRESSES TROP detaillées imprimées TROP CORRECTES GOUVERNELMENTALES de Legislation!!!! sur enveloppe) est fausse (voir logiquement avec buts criminelles et penales) et DESTINATAIRE n'a pas reçu la livraison sans doute! C.-à-d. elle est perdue, disparu.

§3. Par conséquent, loi vous oblige aujourd'hui confirmer la responsabilité de payer la compensation pour mon Chronopost TRES IMPORTANT ET TRES URGENTE! Question penale est pour domain. Il est impossible de "delivrer", à partir d'airport de New York, l'envelope avec code postale de Vigrinia dans zone de Washington D.C., avec ville bien écrit de sud de Washington, où Etat Virginia est aussi bien marqué. Deux heures d'aeroport de New York pour 350 km pour Washington D.C. (Virginia) c'est IMPOSSIBLE et tout sans doute!! est logiquement exprès avec intention par Chronopost des USA! Merci en avance pour me communiquer cette simplicité de compensation évidente. Je vous prie de croire, Monsieur, à l'expression de mes sentiments distingués. Dr.Y.Zagyansky

P.S.(1) Vous pouvez essayer en urgence de recouperer ce "Chronopost" et d'en delivrer avec retard au Distinataire d'enveloppe (en communicant "Le Suivi" par Internet obligatoirement aussi) en payant compensation pour retard (et en diminuant le problème criminelle intentionnel : évident :).

P.S.(2) Il y avait toujours le nom de réceptionniste chez ce Destinateur. Cette seule fois il n'y a pas de telle nom en confirmant la présence de truc intentionnel!

P.S.(3) Si par miracle, ils ont delivré, d'après cela, le Chronopost, je voudrais avoir ce très urgent justificatif et explications claires, comment c'était possible (peut-on toujours faire les deux miracles avec tel Système ?).



Yu.Zagyansky 18th August 2004

CHRONOPOST INTERNATIONAL

End of covering letter in two parallel variants
Yu.Zagyansky 18 Aug. 2004"
beginning of „Mandat International"
beginning of „Mandat International
:La Poste. Mandat International (USA)
pays de destination USA" Yu.Zagyansky

Le suivi de vos envois

ven. 13

VOS ENVOIS

XD104666931FR	Jeu 12/08/2004 17:31	Livraison effectuée

HISTORIQUE - ENVOI N° XD104666931FR

jeu 12/08/2004 17:31	CI UNITED STATES OF AMERICA	Livraison effectuée	Lieu : New-York - US Statut de l'envoi : Envoi livré (publipostage)
jeu 12/08/2004 15:38	CI UNITED STATES OF AMERICA	Envoi reçu par l'agence	Lieu : New-York - US
jeu 12/08/2004 04:14	CHRONOPOST FRANCE	Difficulté rencontrée	Lieu : Roissy - Paris - FR Statut de l'envoi : Envoi reçu Documentation manquante ou incorrecte
jeu 12/08/2004 01:16	ROISSY INTER CHRONOPOST	Envoi sorti de l'agence export	
jeu 12/08/2004 00:50	ROISSY INTER CHRONOPOST	Envoi arrivé dans l'agence export	
mer 11/08/2004 20:27	PARIS BERCY CHRONOPOST	Tri agence de départ effectué	
mer 11/08/2004 19:38	CHRONOPOST	Dépôt point de vente Chronopost	

AUTRE SUIVI :
Pour suivre d'autres envois, saisissez leur numéro dans la case ci-dessous.
Pour saisir plusieurs numéros d'envoi, vous pouvez les séparer par une virgule ou en appuyant sur la touche Entrée ↵

Pour toute information complémentaire, n'hésitez pas à en cliquant ici.

Valider

English | FAQ | Prendre contact | Informations légales | Conditions d'ut

Les sites Chronopost International : Choisissez...

16th Aug. 04
18th Aug. 04

XD 104 666 931 FR

Pour toute information sur votre envoi appelez le Service Clients au
0825 801 801* ou consultez le minitel **3615 ou 3617 Chronopost****
ou **internet : www.chronopost.com**

Votre n° d'envoi est le :

XD 104 666 931 FR Clé: 10 48

*0,98 F TTC (0,14 €) la minute au 01/10/2000
**2,21 F TTC (0,33 €) la minute au 01/10/2000

EXPÉDITEUR Emballage et transport payés. Enveloppe 1. Résistance maximum 250 G

Nom DOCTOR Y. ZAGYANSKY
Adresse ENTRAIDE, 22 RUE STE MARTHE
Code postal 75010
Ville PARIS
Pays FRANCE
Tél
Email: ZagyanskyS.Yuly@laposte.net
Personne à contacter

DESTINATAIRE Exemplaire Expediteur

Nom COMMISSIONER FOR PATENTS
Adresse P.O. BOX 1450, ALEXANDRIA, VIRGINIA
Code postal 22313-1450
Ville ALEXANDRIA
Etat / Province VIRGINIA
Pays USA
Personne à contacter
Tél 1-703-305-32-57

CONTENU DE L'ENVOI
☒ Documents sans valeur commerciale

NOM ET SIGNATURE DE L'EXPEDITEUR
(DR Y ZAGYANSKY)

DATE

TIMBRE À DATER

E PAS DÉTACHER AVEC LE FEUILLET 1

AMÉRIQUE DU NORD

Information on Contracting States B1

UNITED STATES OF AMERICA US

General information

Name of Office: United States Patent and Trademark Office (USPTO)

Location: 220 20th Street S. Crystal Plaza 2, Arlington, Virginia, 22202 United States of America

Mailing address: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 USA

Telephone: +1 (703) 305 3257

Facsimile machine: (1-703) 305 32 30

Teleprinter: TWX 710 955 0671 Arlington, Virginia, USA

E-mail:

Internet: http://www.uspto.gov/go/pct/

RESTRICTIONS À LA PRISE EN CHARGE

D'une manière générale et **sans que cette liste soit limitative,** ne peuvent être pris en charge :
- toutes marchandises relevant des réglementations nationales et internationales sur les produits dangereux tels que notamment définis par les règlements IATA comme, de façon non exhaustive, les munitions, les gaz, les matières inflammables, radioactives, toxiques ou corrosives, ainsi que tous les objets qui, par leur nature ou leur conditionnement, peuvent présenter un danger pour l'environnement, la sécurité des engins de transport, ou endommager les autres colis transportés.
- les bijoux, pierres et métaux précieux, les monnaies, devises, billets de banque, valeurs financières, les titres de paiement (cartes de crédit, chèques, effets de commerce, titres au porteur...), les animaux vivants ou morts, les marchandises sous température dirigée, les armes à feu, les stupéfiants, les objets d'art, les publications ou supports audiovisuels interdits par toute loi ou réglementation applicable, ainsi que les réponses à appels d'offres pour lesquelles CHRONOPOST **propose un service spécifique.**
A l'international, outre les objets relevant des restrictions ci-dessus, ne peuvent être pris en charge :
- les fourrures, alcools non alimentaires, plantes et denrées périssables, valeurs négociables en bourse et tous les objets non admis à l'importation dans le pays de destination.

CONSEILS IMPORTANTS

❶ Pour des raisons douanières, les catégories d'objets suivantes ne sont pas admises dans cette enveloppe : bandes magnétiques, billets d'avion, brochures, catalogues, disquettes, livres, matériel publicitaire, partitions, papeterie, passeports, plans, photographies commerciales, tissu.
Dans certains pays, les journaux, magazines et livres font également l'objet de restrictions.

❷ **Complétez lisiblement au stylo à bille noir et en lettres majuscules** le document de transport. N'oubliez pas d'inscrire le nom de la personne à contacter et son numéro de téléphone pour nous permettre de la joindre en cas de besoin.

❸ Inscrivez l'adresse géographique (numéro et nom de la voie) de votre destinataire : les boîtes postales (PO Box) ne sont pas livrées.

PAYS DESSERVIS

Canada
Etats-Unis d'Amérique
(y compris Alaska, Hawaï et Porto Rico)
Mexique

Pour vérifier une destination :
www.chronopost.com
ou **0825 801 801**.

*0,98F TTC (0,14€) la minute au 01/10/2000

18th August 2004
FOR USPTO

Appl.PCT/EP02/02302. Paris, 16th August 04 (Fax: 1-703-872-9306).
Mail Stop PCT, COMMISSIONER for PATENTS, USPTO, P.O. Box 1450, Alexandria, VA, USA. PCT/EP02/02302

Dear Sir, 11th August 04, I sent the "Chronopost" to this USPTO Official "Mailing address", that was communicated as "delivered" by Internet (see www.chronopost.org, N°XD104666931FR and here) in 2 hours after arrival in New York airport. Very fortunately, I could certainly determine: it is (without doubt) false delivery in New York area but not in D.C. (north of VA) area in 350 km!! to south. In view of thousands and thousands of such letters arriving in USPTO with this address (with postal code of VA close to D.C.) without any problem and moreover with even!! printed geographic location (copy of PCT Applicant's Guide) pasted (it is only at my envelope and with blue colour) on the envelope too (see copy of envelope with telephone too), it looks again like organized crime (Brigandage) of STATE-like post to lie, until end of limit entry date! So instead of special cheque (N°08072) made in dollars ($460), that was in envelope (attached by 4 staples to Form PTO-1390), I had to send again these money by post (see receipt) and separately (this time) to send "simple" registered letter from Central Post (Paris-Louvre N°). This is also text of post letter wherein after this, I assure (as before) presence of all pages, in writing on each page end of previous page and beginning of next page with date and my signature (with cercle) (in order as in Supplement of Covering letter of 08/11/04 with Supplement, copy of Chronopost envelope, Internet track, Receipt of postal sending of $460 as firstly in cercle). Evidently there is no cheque in this 2nd letter.

PCT/EP02/02302

Limited Supplements in Fax: 1. Covering letter of 08/11/04. 2. Copy of Chronopost Envelope (= OPEN BRIGANDAGE of 100% of experienced). 3. Copy of Internet Track with 100% false delivery in N.Y.???? 4. (for basic fee) Receipt of sending of $460. 5. Copy of Receipt of Registered letter. 6. Form PTO-1390. 7. Declaration about optional correction of slips (pp.82, 87). 8. Corrected pp.82 and 87. 9. Copy of my letter to Director of WIPO (first 2 pages, 05/28/04). 10. Copy of cheque, stapled to PTO-1390 (sent in Chronopost).

COVERING LETTER. Yul Zagyansky 18th August 2004

Application N°PCT/EP02/02302, filing date 04th March 2002, title: "End of AIDS for general Virology based on profound science as protein foldings: safe vaccines, universal antimicromial means, mad cow end"

Commissioner of Patents
USPTO
Paris, 11th August 2004

Dr.Y.Zagyansky, Entraide, 22 rue Ste Marthe, 75010
75010 Paris France

Dear Sir, I am entering into National US phase of my above PCT application (see form PTO- 1390 here). §1. Original English text of this Application was transmitted by International Bureau to you, according to your demand (Art.20) (see form PCT/IB/308) and I am entering with this original text. Only optionally, I corrected obvious slips at typing some references (it is only in Supplement of Specification in List of References that were numbered and discribed already in Specification). Even giving of MANY new references IN SPECIFICATION was accepted without any problem by EPO-IPEA (see copy here) at my another application (PCT/IB00/00843) according to direct law ("EPO Guidelines" §CII-4.3.). (And it was justly accepted at EPO National entry of this Application).

§2. Because, the US law forbids reference (in dependent claims) for two previous claims connected with "and", I very simply and naturally elimine one of references in such claims. I did it for International phase only for easier orientation although it was not necessary.

§3. The International Search of this application is done by 100% unlegal way and was not corrected neither by EPO (ISA) nor by with help of Director of WIPO. It is too evident demonstrative intentional GROTESQUE. See here my letter of 05/28/04 and 06/17/04 to Director of WIPO (fixed with stamp of French Office in my letter of 06/22/04 to its Director) and also, separately, the copy of this letter of 05/28/04- 2 first pages.

§4. I am original sole independent Inventor of this Application with small unity status, who does not have any agreement concerning this application.

!!!§5. In view of very special "strange" course of my Applications, I must ask here very important question about "Notice of Abandonment". In US law, concerning "Certificat of mailing or transmission" (37 CRF §1.8, §512 MPEP) there is no mention about, even declaration, FOR nonreceiving of USPTO letters (ONLY of USPTO letters!), but only text about Certificat of mailling or transmission of Applicant letter. Does it mean that USPTO finally send the registered letter wherein USPTO is sure about their receiving by Applicant and such Declaration (for nonreceiving of USPTO letter) is not needed consequently? Thank you very much for forward explanation of this TOO important information. The heavy common truth is coming from Governmental Office? Thank you very much (only due to Internet making USPTO men) for very net comings!

Sincerely yours Dr.Y.Zagyansky. Supplements: 1. Forms PTO-1390, PTO/SB/01, PTO/SB/09. 2. Copy of Cheque for $460 for basic fee, attached to Form PTO-1390 with staples. 3. Declaration about optional replacement (100% slips moreover with Supplement of reference List) of pp.82 and 87 with new pp.82 and 87 in 3 copies (with replaced with IPEA p.52 of PCT/IB00/00843). 4. Declaration about too simple eliminations from dependent claims of reference for several previous claims with pp.92, 93, 96-98 (concerning claims 3-5, 7-9, 11). 5. Form PCT/IB/308. 6. My letter to Director of French Office (with its stamp of 22 June 04) with my letter to Director of WIPO of 28th May 04 and 17th June 04. 7.My letter to Director of WIPO of 28th May 2004 (2 first pages). 8. Abstract of this Application (3 copies). All replaced pages of all copies are signed (verso) by me (as well all Forms at all pages) with date of 11th August 2004.

VERSO

In the case of receiving of both sums, each of $460, to communicate immediately by e-mail: zagyansky5.yuly@laposte.net. Immediately, I shall enter my Appl. PCT/IB03/03315 for US Natl.phase with help of this resting sum. 9. FORM PTO-2038 IN two PARALLEL VARIANTS. Yul Zagyansky 18 Aug. 2004

Yuf Yufbagus 18th August 2004

begin as my page d'enveloppe of chronopost : « XD 104666 931 FR pour toute information sur votre ... » end of Form PTO-2038 vers. 2 : « correct one alternative de §1). »

IMPORTANT. AT SENDING OF MONEY AT POST, AT CHECKING, I HAD PUT THE CITY „ALEXANDRIA" IN ALL THREE COPIES OF „MANDAT INTERNATIONAL" WITH MY SPECIAL BLACK SIGNATURE PEN, AS HERE

Yufbagus

VERSO

DECLARATION ABOUT ONLY too simple eliminations from dependent claims of references for several previous claims.

I, Zagyansky Yuly, sole Inventor of Application PCT/EP02/02302, make the following too simple elemination of unneeded references for numerous precedent claims (generally making simple photocopies of published pages).

p.92-40 (line 40) (for claim 3): claim (instead of: claims).

p.93-1 (for claim 3): 1 [instead of: 1(8, 10, 14) and 2].

p.93 (lines 8,9) (for claim 5): claim 1 [instead of: claims 1 (1-5, 8].

p.96 (lines 7,8) (for claim 7): claim 6 [instead of: claims 1(16), 2 and 6].

p.97-7 (for claim 8): claim 7 [instead of: claims 1, 2, 6 and 8] (also too obvious slip: 7 instead of 8).

p.97 (lines 27, 28) (for claim 9): claim 6 [instead of: claims 1, 2 and 6 (19,20)].

p.98-20 (for claim 11): claim 6 (instead of: claims 1 and 6).

Paris, 11th August 2004. All pages are signed by me verso with date of 08/11/04.

Yuly Zagyansky 18th August 2004

19 Aug. 2004 (1st exp.) one exp. [illegible]
end p. 87 [illegible] exp: „ Research (to see also „ Generalities
§ C III - 2.2.) and "
legions p. 92 (1st exp): „ receptor cell "

10/505534
DT15 Rec'd PCT/PTO 24 AUG 2004

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost unvisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim

[redacted] 18th August 04 1st exp.

end "Declaration about [redacted]y to Simple": with date of 08/11/04. [redacted] 18th August 2004".

beginning of p 92 (2nd exp): "receptor cell machinery"

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost unvisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim

Y.W.Bergs 19th August 2004 (1) 2nd sup 2nd exp.
end p 92 1st [redacted]:.. accordans clause "
beginning p 92 3rd exp:.. exception all machinery (of "

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost unvisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim

Yusuf Hamied 14th August 2004 3rd reply.
Enclosed [redacted] 2nd reply: "entirely accordant claim"
Regarding: "I claim", The substances "

1

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the β-chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1 /and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as β-chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following caracteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4). The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsable for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

[redacted] 18th August 2004 1st exp
end p 92 3d exp [redacted] for the vitiates entry accusing claim"
Bejsovec p. 93 2nd exp: " 1 claim 4. The substances /Ref. "

1

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the β-chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1 /and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as β-chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following caracteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4). The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsable for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

[redacted] 11th August 2004 2nd exp.

end p. 93 1st exp: [redacted]."

Legislation p. 93 3rd exp: "1 claim 4. The substances /Art. 52 (4) "

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the β-chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1 /and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as β-chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following caracteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4) The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsable for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

18th August 2004 3rd exp.

end p[redacted] 2nd exp: „ cytoplasm, takes place."

beginning p. 96 1st exp: „ hydrogen homologous.

Contains between CD4"

hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the α1 and α2 domains of the MHC α-chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I α chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR α-chain (also without pair) to switch the "Du-2T" dissociation from the MHC α3 domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

Yes please 18th August 1st comp:
and p. 93 3d comp: „ in cytoplasm, takes place "
before p. 96 (2nd) 2nd comp: „ hydrogen homologous
liaisons between ".

hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the α1 and α2 domains of the MHC α-chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I α chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR α-chain (also without pair) to switch the "Du-2T" dissociation from the MHC α3 domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

18 Aug 04 2nd exp.

(end p 98 [illegible] exp)

end p. 96 1st exp: "(discusses"

beginning p. 96 3d exp: "hydrogen bonding
exists between CD4 and"

hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the α1 and α2 domains of the MHC α-chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I α chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR α-chain (also without pair) to switch the "Du-2T" dissociation from the MHC α3 domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

Yuffdays 18 Aug. 2004 3 emp.
end p. 96 "emp: in pathology
(disease" beginning p. 97 1st emp:
"as dead"

as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like ="Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mashrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mashrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signallings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim 6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yuliya 18th Aug. 2004 1st sep.

end p.96 3d [redacted]:u – aggregation in pathology

(cardiac " beginning p.57 2nd sep:

" as lead Cons on "

as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like ="Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mashrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mashrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signallings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim 6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yuri Tarasov 18 March 2004 End exp
(end p. 97 3rd exp) Yuri Tarasov
end p. 97 1st exp: „ where he 3' "
beginning p. 97 3rd exp: „ as Jesus Christ on Jacob- "

as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like ="Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mashrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mashrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signallings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim 6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yu [redacted] 18th Aug. 2004 3d exp.

end p. 9[redacted] 2nd exp: „ to the cytoplasm
where the 3' "

before NOS p-98 1st exp; the RNA part "

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

1st exp. p. 98

end p. 97 3d exp: „ go to the cytoplasm where he
3' "

(p. 97 / 4 cyclers) 18h Aug. 04

beginning p. 98 2nd exp: „ the RNA part
serves as the "

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

Yu Pan 2nd exp - 18th Aug. 04 „
end of p. 98 1st exp: „ Vessels according Claus
6(12) " beginning p. 98, 3d exp: „ In Adult
part serves as the guise "

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

Yu Jhang 13 Aug. 2004 3rd copy

end p. 98 : " [redacted]spirit vertical accuracy class 6(12). " beginning Form PCT/IB/308 : " PATENT COOPERATION TREATY WO 02/51233 PCT/EP02/02302 From the International Bureau ".

Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (mϕ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and preudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain mϕ due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signallings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functionning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: mϕ mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral ,anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

18 Aug. 04 1st emp.
end p. "... do Director of INPI".
Yours sincerely, pp. E. De Bruce.
Director 1521"
beginning p. Without 2nd emp: "the AIDS principal"

Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (mϕ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and preudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain mϕ due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signallings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functionning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: mϕ mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral ,anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

Yu Rogers 18 Aug. 2003 2nd corp.

end p. 99 1st corp: „ perfected hypnotics"

before p. 99 3d corp: „ All AIDS genocidal mysteries"

Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (mϕ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and preudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain mϕ due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signallings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functionning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: mϕ mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral ,anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

YeRa 18 August 2004 3rd emp.
end p[illegible] 2nd emp: a Corma; perfected hypothetical
sequence p. PTO-2038 variant 1; PTO-2038
(02-2003)

PTO/SB/09 (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) & 1.27(b))–INDEPENDENT INVENTOR	Docket Number (Optional)

Applicant, Patentee, or Identifier: *Y.Zagyansky*

Application or Patent No.: **PCT/EP02/02302**

Filed or Issued: **04 March 2002**

Title: **End of AIDS for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end.**

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
- ☒ the application identified above.
- ☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
- ☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

Dr.Y.Zagyansky (Dir.rech.Equ.)		
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
Signature of inventor	Signature of inventor	Signature of inventor
18th August 2004		
Date	Date	Date

Yuly Agne 18th August 2004
Form PTO/SB/01 : "or 02LR attached
hereto." Registering copy of cheque (stapled)
stapled to Form PTO-1390 : "Code: Agence
Société générale groupe Paris seine AMONT
Logistique usifice.."

10/505343

DT15 Rec'd PCT/PTO 24 AUG 2004

Yuly Yulybayer 18th Aug. 04
End of Form PTO-1390. "applications to pending status. Signature name registration number beginning Form PTO/SB/103 : to PTO/SB/05 (12-97) Approved for use ..."

US

10/505353
DT15 Rec'd PCT/PTO 24 AUG 2004

PTO/SB/01 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: ☐ ust er mber [ ] OR ☒ Correspondence address below			
Name: Y.Zagyansky			
Address: Entraide, 22 rue Ste Marthe			
City: Paris	State:	ZIP: 75010	
Country: France	Telephone:	Fax: e-mails: zagyansky5.yuly@laposte.net and zagyansk@cyberport.tm.fr	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:	☐ A petition has been filed for this unsigned inventor		
Given Name (first and middle [if any]): Yuly		Family Name or Surname: ZAGYANSKY	
Inventor's Signature: Yulybayer 18th August 2004			Date: 11th August 2004
Residence: City: Paris	State:	Country: France	Citizenship: France
Mailing Address: Entraide, 22 rue Ste Marthe			
City: Paris	State:	ZIP: 75010	Country: France

NAME OF SECOND INVENTOR	☐ A petition has been filed for this unsigned inventor		
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature			Date
Residence: City	State:	Country:	Citizenship:
Mailing Address			
City	State:	ZIP:	Country:

☐ Additional inventors or a legal representative are being named on the _____ supplemental sheet(s) PTO/SB/02A or 02LR attached hereto.

PTO/SB/01 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☒ Declaration Submitted With Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	
First Named Inventor	ZAGYANSKY Yuly
COMPLETE IF KNOWN	
Application Number	
Filing Date	
Art Unit	
Examiner Name	

I hereby declare that: ZAGYANSKY Yuly

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"End of AIDS for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end"

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 03/04/2002 as United States Application Number or PCT International Application Number PCT/EP02/02302 and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Co Yes	Attached? No
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐

☐ Addit on l for ign ap cat on umbe s a e l st d on sup men al p iority ta sh et PDD SB/02B a ta ed here

Yuly Zagyansky 18th August 2004